Spatio-temporal analyses reveal infectious disease-driven selection in a free-ranging ungulate.

R Soc Open Sci

Wildlife Genomics and Disease Ecology Laboratory, Department of Veterinary Sciences, Program in Ecology, University of Wyoming, Laramie, WY 82071, USA.

Published: August 2021

Infectious diseases play an important role in wildlife population dynamics by altering individual fitness, but detecting disease-driven natural selection in free-ranging populations is difficult due to complex disease-host relationships. Chronic wasting disease (CWD) is a fatal infectious prion disease in cervids for which mutations in a single gene have been mechanistically linked to disease outcomes, providing a rare opportunity to study disease-driven selection in wildlife. In Wyoming, USA, CWD has gradually spread across mule deer () populations, producing natural variation in disease history to evaluate selection pressure. We used spatial variation and a novel temporal comparison to investigate the relationship between CWD and a mutation at codon 225 of the mule deer prion protein gene that slows disease progression. We found that individuals with the 'slow' 225F allele were less likely to test positive for CWD, and the 225F allele was more common in herds exposed to CWD longer. We also found that in the past 2 decades, the 225F allele frequency increased more in herds with higher CWD prevalence. This study expanded on previous research by analysing spatio-temporal patterns of individual and herd-based disease data to present multiple lines of evidence for disease-driven selection in free-ranging wildlife.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355672PMC
http://dx.doi.org/10.1098/rsos.210802DOI Listing

Publication Analysis

Top Keywords

disease-driven selection
12
selection free-ranging
12
225f allele
12
mule deer
8
disease
6
cwd
6
selection
5
spatio-temporal analyses
4
analyses reveal
4
reveal infectious
4

Similar Publications

Background: Atherosclerosis is a lipid mediated chronic inflammatory disease driven my macrophages (MØ). Protein Kinase C - epsilon (PKCɛ) is is a serine/threonine kinase involved in diverse cellular processes such as migration, growth, differentiation, and survival. PKCɛ is known to act in a context dependent manner within heart, however, its role in atherosclerosis is unknown.

View Article and Find Full Text PDF

Angiotensin receptor blockers modulate the lupus CD4+ T cell epigenome characterized by TNF family-linked signaling.

JCI Insight

December 2024

Division of Rheumatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States of America.

In systemic lupus erythematosus (lupus), environmental effects acting within a permissive genetic background lead to autoimmune dysregulation. Dysfunction of CD4+ T cells contributes to pathology by providing help to autoreactive B and T cells, and CD4+ T cell dysfunction coincides with altered DNA methylation and histone modifications of select gene loci. However, chromatin accessibility states of distinct T cell subsets and mechanisms driving heterogeneous chromatin states across patients remain poorly understood.

View Article and Find Full Text PDF

Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease-induced and treatment-related cytopenias. Venetoclax, a selective BCL-2 inhibitor, in combination with azacitidine, a hypomethylating agent, is currently being investigated in patients with previously untreated higher-risk MDS.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is a multifactorial disease driven by genetic and epigenetic alterations that modulate specific metabolic pathways. Despite the availability of effective treatments like 5-fluorouracil (5-FU), pharmacological therapy for CRC still faces significant challenges, including drug resistance, toxicity, and limited specificity. Therefore, discovering new compounds remains critical to overcoming these barriers and expanding treatment options.

View Article and Find Full Text PDF
Article Synopsis
  • Acute myeloid leukemia (AML) has a poor prognosis mainly due to the relapse driven by therapy-resistant leukemia progenitor/stem cells (LPCs), leading to the development of peptide-based immunotherapy targeting these cells to improve patient outcomes.
  • A therapeutic vaccine called AML-VAC-XS15 was created, consisting of specific peptides from common AML mutations, and is being tested in a phase I clinical trial for its effectiveness and safety in AML patients in remission.
  • The study is ethically approved and aims to evaluate the vaccine's ability to generate immune responses and assess its preliminary clinical efficacy while ensuring patient safety through monitoring over two years.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!